Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06639607 · ClinicalTrials.gov registry record · Phase 1
PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma
A Phase 1 study, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 68
- Enrollment target
NCT06639607 is a Phase 1 study that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 68 participants.
The verdict
NCT06639607, a Phase 1 study, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 68 participants
- Enrollment target
Study Summary
This is a multisite, phase I/II clinical trial in children and young adults with newly-diagnosed high-grade glioma (HGG), diffuse midline glioma (DMG) and recurrent HGG/DMG, Medulloblastoma (MB), or ependymoma (EPN) to determine the safety, immunogenicity, and efficacy of a CMV-directed peptide vaccine plus checkpoint blockade.
Interventions
- DRUG Temozolomide
- BIOLOGICAL Nivolumab
- BIOLOGICAL PEP-CMV vaccine
- BIOLOGICAL Tetanus booster
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2026-06-30 |
| Est. Completion | 2051-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06639607
The ClinicalTrials.gov registry entry for NCT06639607 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Temozolomide is the first listed.
NCT06639607 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06639607 about?
NCT06639607 is a clinical study titled "PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma". This is a multisite, phase I/II clinical trial in children and young adults with newly-diagnosed high-grade glioma (HGG), diffuse midline glioma (DMG) and recurrent HGG/DMG, Medulloblastoma (MB), or ependymoma (EPN) to determine the safety, immunogenicity, and efficacy of a CMV-directed peptide vacc...
What is the current status of trial NCT06639607?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 68 participants. The study started on 2026-06-30. Estimated completion is 2051-06-30.
What interventions are being tested in trial NCT06639607?
The interventions under investigation include: Temozolomide (DRUG), Nivolumab (BIOLOGICAL), PEP-CMV vaccine (BIOLOGICAL), Tetanus booster (BIOLOGICAL).
Who is sponsoring clinical trial NCT06639607?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.